PREVAIL
FOX CHASE CANCER CENTER | ANNUAL REPORT 2018
“True to our century-long legacy, we distinguished ourselves through proof of performance, expansion of facilities and services, recruitment of new talent, and partnerships with key figures in our community.”

— Richard I. Fisher, MD, president and CEO
COMMUNITY

- OPENING OF EAST NORRITON CAMPUS
- LOCAL LEADERS SUPPORT FOX CHASE
- UNITE FOR HER
- PATIENT-TO-PATIENT NETWORK
- NURSING DEPARTMENT EARNS MAGNET DESIGNATION
Opening of East Norriton Campus
On May 8, Fox Chase Cancer Center opened a new outpatient facility in East Norriton, Pennsylvania. Located on the campus of Suburban Community Hospital, Fox Chase Cancer Center East Norriton – Hospital Outpatient Center offers access to Fox Chase’s specialized team of providers in a suburban setting, allowing patients to be treated closer to home.

The location features two full floors of clinical space, including a linear accelerator for radiation treatments, flexible clinic space with seven exam rooms, an infusion center with seven infusion chairs, and a healing garden.

From the beginning, Fox Chase East Norriton offered hematology and medical oncology services, including chemotherapy and immunotherapy, for most types of cancer and benign blood conditions, radiation oncology, and surgical consultations. It has since expanded to offer genetic counseling and testing, as well as plastic and reconstructive surgical consultations to address physical changes that can result from cancer treatment. Through genetic counseling and testing, patients can learn about genetic factors that may increase the risk of developing cancer, and get help with long-term plans to reduce their risk.

Patients at Fox Chase East Norriton also have access to nurse navigation services, clinical trials, and other support services offered at the Fox Chase Main Campus. Services will continue to expand at Fox Chase East Norriton to provide a convenient option in the suburbs.

Local Leaders Support Fox Chase
Fox Chase deepened its ongoing relationships with several state and federal leaders in 2018. As a major employer and healthcare provider within Pennsylvania’s 13th Congressional District, Fox Chase has a dramatic impact on this region. Congressman Brendan F. Boyle visited the Center over the summer, and has been a partner in supporting the Center’s clinical, research, and outreach efforts in the community.

In February, State Senator Christine Tartaglione and State Representative Kevin Boyle presented Fox Chase with a check for $500,000 from the Redevelopment Assistance Capital Program of the Commonwealth of Pennsylvania. This funding will support a planned expansion of the infusion room.

The Office of Community Outreach is Fox Chase’s bridge to the community, reaching more than 13,000 people in the region in 2018. Outreach efforts included multiple health and wellness events. Numerous area leaders hosted or jointly participated, including State Representative Matt Bradford at the Meadowbrook Senior Living Community, State Representative Steve McCarter for the Senior Expo in Elkins Park, and State Representative Christopher Rabb for the Grown Folks Festival in Philadelphia. Fox Chase was one of more than 40 vendors at the Fox Chase National Night Out event hosted by State Representative Boyle at the Fox Chase Elementary School.

Additionally, the Fox Chase Mobile Screening Unit, in partnership with Flyers Charities, provided breast cancer screening for the constituents of Representatives Boyle, Mary Jo Daly, John Sabatina, and Kate Harper.

Unite for Her
The non-profit organization Unite for Her has partnered with Fox Chase to bring a wide range of wellness services to breast cancer patients. They provide nutrition counseling, yoga, meditation, exercise therapy, acupuncture, massage, reiki, and professional counseling all free of charge. Unite for Her held several wellness days at Fox Chase throughout the year, where patients learned more about services that can complement their medical care. Patients were given a passport, allowing them to utilize the services from area vendors and providers throughout the year.

Patient-To-Patient Network
In 2018, Fox Chase launched the Patient-to-Patient Network, a phone-based support program for cancer patients. The program connects patients beginning their cancer journey to volunteers going through similar experiences, providing support, guidance, and encouragement.

“Fox Chase East Norriton is a true extension of the main campus, where patients receive the same expertise and quality of care. We work hard to bring what is special about Fox Chase to this new location.”
— Christine Gorrell, RN, MSN, OCN, director of the East Norriton Campus of Fox Chase Cancer Center
The Department of Nursing successfully achieved its fifth consecutive Magnet® designation for nursing excellence from the American Nurses Credentialing Center. Fox Chase has held Magnet status continuously since 2000, and is one of only nine hospitals globally to earn it five times.

The Magnet Recognition Program is regarded as the nation’s highest form of recognition for excellence in nursing. Applicants are scored on patient satisfaction, nurse satisfaction, adherence to standards for improving the quality of patient care, inter-professional collaboration, leadership of the chief nurse executive in supporting professional practice, and continued competence of nursing personnel.

Nursing Department Earns Magnet Designation

The Department of Nursing successfully achieved its fifth consecutive Magnet® designation for nursing excellence from the American Nurses Credentialing Center. Fox Chase has held Magnet status continuously since 2000, and is one of only nine hospitals globally to earn it five times.

The Magnet Recognition Program is regarded as the nation’s highest form of recognition for excellence in nursing. Applicants are scored on patient satisfaction, nurse satisfaction, adherence to standards for improving the quality of patient care, inter-professional collaboration, leadership of the chief nurse executive in supporting professional practice, and continued competence of nursing personnel.

“Knowing what to expect from survivors greatly reduced my anxiety about starting treatment and made me more confident in my decision to seek treatment at Fox Chase,” said one recently matched patient. Newly diagnosed patients are carefully matched with cancer survivors who are specially trained. Patient-to-Patient Network volunteers help address patient concerns, share personal journeys, and provide empathetic support and encouragement.

To date, the program has more than 100 volunteers representing a wide range of cancers, and is still recruiting. The program is coordinated through the Philip E. and Naomi P. Lippincott Resource and Education Center, a patient and family learning center designed to provide information about cancer risk, prevention, screening, and treatment options such as clinical trials.

— Joan Lautenbacher, lung cancer survivor
- CAR T-CELL THERAPY
- REMEMBERING GERALD E. HANKS
- LUTHERA: A NEW DRUG FOR NEUROENDOCRINE TUMORS
- WELCOMING MARIUSZ A. WASIK
- AMBULATORY HEMATOLOGY/ONCOLOGY OFFICE
- PALLIATIVE CARE FELLOWSHIP
- CY SVIEW
- MASTER CLINICIANS
- SURGICAL ONCOLOGY QUALITY INITIATIVES
- WELCOMING NEW PHYSICIANS
CAR T-cell therapy
After passing a rigorous six-month review process, Fox Chase began providing CAR T-cell therapy to eligible leukemia and lymphoma patients. A recently developed intensive form of immunotherapy, CAR T-cell therapy allows doctors to extract and genetically alter T-cells from a patient’s blood, then re-infuse them into the patient. The modified cells are programmed to target and eliminate cancer cells. This approach has shown great promise in treating certain blood cancers, with success rates up to 90 percent for some types of disease.

Fox Chase now provides both FDA-approved CAR T-cell drugs: Kymriah (tisagenlecleucel) from Novartis and Yescarta (axicabtagene ciloleucel) from Gilead Sciences, Inc. Kymriah is approved for the treatment of relapsed or treatment-resistant B-cell acute lymphoblastic leukemia in children and adolescents, as well as for adults with relapsed or refractory large B-cell lymphoma. Yescarta is the first CAR T therapy approved for the treatment of adults with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, such as chemotherapy.

Henry Fung, MD, FACP, FRCPE, director of the Fox Chase-Temple University Hospital Bone Marrow Transplant Program (BMT), leads the institution’s CAR T-cell therapy practice. During the past year, Fung opened four new clinical trials within the BMT for patients with leukemia, Hodgkin’s lymphoma, and non-Hodgkin’s lymphoma. Fung is a world-renowned expert in bone marrow and stem cell transplantation, and specializes in treating a range of blood cancers. Under his leadership, the BMT performs more than 100 transplants each year.

Remembering Gerald E. Hanks
Gerald E. Hanks, MD, a giant in the world of radiation oncology and longtime member of the Fox Chase community, died on December 20, 2017 at the age of 83. Hanks served as chair of the Department of Radiation Oncology at Fox Chase for 16 years, retiring in 2001. He is credited with establishing the department’s national prominence. After he retired, he was honored by Fox Chase with the creation of the Gerald E. Hanks Chair in Radiation Oncology, which is held by Eric M. Horwitz, MD, FABS, FASTRO, the current chair of the Department of Radiation Oncology. A symposium honoring Hanks’ life and legacy was held March 22, 2018 at Fox Chase, with several renowned radiation oncologists from across the country delivering tributes.

Lutathera: A New Drug for Neuroendocrine Tumors
Patients with neuroendocrine tumors got a new treatment option at Fox Chase this year in Lutathera. Neuroendocrine tumors are among the most difficult tumors to diagnose. They can develop anywhere in the body, behave differently based on where they grow, and patients with these tumors often exhibit symptoms that are similar to many other diseases. Lutathera works by carrying a
Welcoming Mariusz A. Wasik

A significant addition to the Center’s leadership team, Mariusz A. Wasik, MD, joined Fox Chase as chair of the Department of Pathology as well as Associate Director of the Cancer Center. His research focuses primarily on aberrant cell signaling, the underlying genetic and epigenetic mechanisms in lymphomas, the development of new diagnostic and monitoring tools, and the identification of novel treatment approaches based on the unique biology of malignant cells. In addition to continuing this research, Wasik will play a prominent role in supporting Temple University Health System’s cancer service line and strengthening the portfolio of molecular diagnostics and genomic testing within Fox Chase. He is slated to be installed as the Stanley and Stella Bayster Chair in Molecular Diagnostics.

“The amazing thing about Fox Chase is the people. It wasn’t just one person, but a whole team of people, who helped save my life and gave me the best care possible.”
— Preston Moyer, mesothelioma survivor

Radioactive component that binds to somatostatin receptors on the tumors and slowly destroys neuroendocrine tumor cells from within, leaving healthy cells unharmed. Clinical trials at Fox Chase and elsewhere have found that Lutathera is an effective treatment for these elusive tumors. For Pam, a Fox Chase patient who had neuroendocrine tumors surgically removed from her small bowel and breast, Lutathera has led to a 15 to 20 percent reduction in the lesions on her liver and lymph nodes.

“This is truly a personalized treatment developed specifically for patients who have the somatostatin receptor markers,” said Paul F. Engstrom, MD, FACP, a medical oncologist and national leader in the treatment of neuroendocrine tumors. “A large percentage of patients with extensive disease and large differentiated tumors may qualify for this new treatment, which has been a huge advancement.”

Fox Chase has long been a leader in the treatment of neuroendocrine tumors. The Center was the first hospital in the greater Philadelphia region to offer the Gallium-68 dotatate PET/CT imaging scan that takes much less time than routine nuclear medicine imaging and exposes the patient to less radiation.

Ambulatory Hematology/Oncology Office

The Fox Chase Cancer Center Ambulatory Hematology/Oncology Office

“The amazing thing about Fox Chase is the people. It wasn’t just one person, but a whole team of people, who helped save my life and gave me the best care possible.”
— Barry Taitelman, kidney cancer survivor

“Everyone at Fox Chase, from the doctors and nurses to the support staff, made me feel comfortable and welcome at a time when I felt most vulnerable. They care about their patients above all else and it truly shows.”
— Barry Taitelman, kidney cancer survivor
opened in January in the Physicians’ Office Building at Jeanes Hospital. This collaboration provides outpatient cancer care in a convenient space.

The new office specializes in treating patients with benign and malignant blood disorders, such as leukemia, lymphoma, clotting problems, and anemia, as well as solid tumors, such as lung, breast, prostate, and sarcoma. Patients who are treated in this office have the same access to clinical trials and novel treatments as all Fox Chase patients.

Rashmi Khanal, MD, section chief for hematology/oncology at Jeanes Hospital, leads the practice. Vijaykumar Gandhi, MD, an attending physician at Jeanes, helps support this clinic. Several Fox Chase hematologists and oncologists treat and evaluate patients here.

**Palliative Care Fellowship**

The Pain and Palliative Care Program recruited Stephanie Zankman, DO, to Fox Chase as the first hospice and palliative medicine fellow. The one-year program trains leaders and clinicians in the care of patients with serious illnesses by building skillsets that include expertise in pain and symptom management, communication, complex psychosocial care, and end-of-life care. Molly Collins, MD, director of medical education for the Pain and Palliative Care Program, directs the fellowship. The program supports one fellow each year and includes rotations at Fox Chase, the Hospice of the Visiting Nurse Association of Greater Philadelphia, and Temple University Hospital.

**Cysview**

This year Fox Chase began offering Blue Light Cystoscopy with Cysview, a revolutionary diagnostic and treatment approach designed to improve detection and removal of early stage bladder cancer with greater accuracy and to reduce recurrence.

When symptoms and blood tests suggest that an individual may have bladder cancer, doctors do a visual inspection of the interior wall of the bladder using a cystoscope — a thin tube with a light and video camera on the end — in a procedure called a cystoscopy.

While larger non-muscle invasive bladder cancer tumors may be visible using white light, smaller cancerous areas may not be easily detected because their color can look the same as surrounding healthy tissue.

In the new approach, doctors use a cystoscope equipped with both white and blue light and administer an optical-imaging drug called Cysview that is absorbed by cancer cells. When viewed under the blue light, early stage tumors and lesions glow pink against the healthy tissue, which shows up blue. Research shows that this approach significantly reduces the chances of recurrence, because it allows surgeons to perform a more complete removal of the cancer. Fox Chase is among a select number of institutions around the country to offer this approach.

**Master Clinicians**

Richard Greenberg, MD, FACS, professor of urology and urologic surgery, and Elin Sigurdson, MD, PhD, FRCS (C), professor of general surgery, earned the designation of master clinician this year. The distinction is granted to physicians who have displayed sustained excellence in patient care.

"After five rounds of radiation, scans showed that not only had the bleeding stopped, but the tumor was completely gone and the other tumors had shrunk in half. In three months, my health had completely changed."

— Mahmood Saeed, kidney cancer survivor
Surgical Oncology Quality Initiatives

Under the leadership of Chair Robert G. Uzzo, MD, FACS, the Department of Surgical Oncology launched several initiatives in 2018 aimed at improving the quality and safety of patient care, and the efficiency of the operating rooms. The American College of Surgeons National Surgical Quality Improvement Program designated Fox Chase as a meritoriously performing hospital on its All Cases and High Risks lists.

New initiatives this year include Enhanced Recovery After Surgery, an approach designed to help improve recovery from surgery; an ongoing Perioperative Risk Study that studies methods that aim to further reduce the risk of death and serious complications after major cancer surgery; and SwipeSense, a technology that increases hand hygiene awareness among anyone who may have direct contact with patients.

“Dr. Richard Greenberg performed a radical cystoprostatectomy and urostomy that saved my life. I had many physical changes to cope with, and Dr. Greenberg was in constant contact with my wife and me. He not only preserved my life, but supported me after surgery to adapt to my new lifestyle. He showed a concern not often seen in a surgeon.”
— Paul Cervone, bladder cancer survivor

Welcoming New Physicians

This year Fox Chase welcomed 23 new clinicians to the faculty in a variety of roles. The Department of Hematology/Oncology added Carlyn Tan, MD, who also completed a fellowship at Fox Chase, Rashmi Khanal, MD, who leads the Hematology/Oncology Program at Jeanes Hospital, board-certified oncologist Jason A. Incorvati, MD, who treats patients primarily at Fox Chase East Norriton, Rishi Jain, MD, who treats patients at the Temple Health Northeastern Ambulatory Care campus, board-certified medical oncologist Jason A. Incorvati, MD, who treats patients primarily at Fox Chase East Norriton, Rishi Jain, MD,
MS, DABOM, and Pooja Ghatalia, MD, who also completed a fellowship at Fox Chase. The Department of Surgical Oncology added physician-researcher Shreyas S. Joshi, MD, who also completed a urologic oncology fellowship at Fox Chase and the Department of Radiation Oncology welcomed Sumeera Kumar, MD, Randi Cohen, MD, MS, who primarily treats patients at Fox Chase Cancer Center East Norriton, and Sangeeta K. Tyerech, MD, who primarily treats patients at the UHS Prostate Treatment Center.

The Department of Diagnostic Imaging added board-certified radiologist Laura Levin, MD, Meghan Boros, MD, and Andrea M. Abbott, MD. The Department of Medicine welcomed dermatologist Abhishek Aphiile, MD, hospitalist Hayley E. Walker, MD, interventional gastroenterologist Jennifer Tome Higa, MD, and Julio Noriega, MD, a pulmonologist. Kristen Whitaker, MD, a specialist in breast cancer genetics and prevention, joined the Department of Clinical Genetics.

The Department of Pathology welcomed hematopathologist Reza Nejati, MD, physician-researcher Y. Lynn Wang, MD, PhD, FCAP, and named Mariusz A. Wasik, MD, the new chair of the department and associate director of the cancer center.

“The level of teamwork and communication amongst the doctors was reassuring. Even though I felt overwhelmed by my multiple surgeries, treatments, and diagnoses, I took immense comfort in the prompt actions taken by my team of physicians.”

— Thomas Myers, melanoma and prostate cancer survivor

“The clinical trial I’m in gave me my life back. With everything I had to worry about, I never second-guessed that I was in the place that was giving me the best options to survive. Once I came to Fox Chase, I knew I was where I need to be.”

— Susie Barton, lung cancer survivor

“TOP: A nurse at work. BOTTOM: A quiet moment in the infusion room
RESEARCH

- PLIMACK RECEIVES STAND UP TO CANCER GRANT
- THE MARVIN & CONCETTA GREENBERG PANCREATIC CANCER INSTITUTE UPDATE
- PARTNERSHIP WITH UNIVERSITY OF DELAWARE
- WELCOMING PAUL M. CAMPBELL
Elizabeth Plimack, MD, MS, chief of the Division of Genitourinary Medical Oncology at Fox Chase, was awarded a $2.9 million Stand Up To Cancer Catalyst Research Grant to investigate whether the drug guadecitabine can reverse the resistance of some bladder cancers to immunotherapy checkpoint inhibitors. Plimack will work with Peter Jones, PhD, chief scientific officer of Van Andel Research Institute.

While immunotherapy has shown great success in some patients, others have not had the same response. Patients whose tumors grow despite immunotherapy may have parts of their DNA silenced, meaning antigens cannot be expressed to start the tumor rejection process. Guadecitabine can potentially remove this silencing, allowing checkpoint inhibitor immunotherapy to work effectively.

The Marvin & Concetta Greenberg Pancreatic Cancer Institute Update

The Marvin and Concetta Greenberg Pancreatic Cancer Institute, made possible through a transformational gift from Philadelphia philanthropist Concetta Greenberg, has grown impressively since its September 2017 inception. Greenberg’s multi-million-dollar commitment—the largest single gift in Fox Chase history—has elevated the Center’s work in pancreatic cancer research and treatment.

Under co-leaders Igor Astsaturov, MD, PhD, and Edna Cukierman, PhD, the Institute made great strides in its first full year, earning multiple grants and adding key members to the team.

In addition to full time researcher...
Award-winning pancreatic cancer researcher Paul M. Campbell, PhD, joined Fox Chase’s Cancer Biology Program in February. He has earned multiple clinical and translational grants and awards for his work on cancer signaling, progression, and metastasis. Previously he led a lab that studied tumorigenesis driven by the activation of the protooncogene K-Ras. At Fox Chase, Campbell has continued his research focus in these areas, with the overall objective of discovering and validating new targets for drug development and finding novel biomarkers for earlier detection and therapeutic monitoring.

Campbell is an assistant professor, and a member of The Marvin and Concetta Greenberg Pancreatic Cancer Institute at Fox Chase. He holds multiple patents related to cancer therapeutics.

“As an NCI-designated Comprehensive Cancer Center, it is our duty to train the next generation of engaged, science-literate, health care consumers, and encourage individuals to get involved in the enterprise of discovery.”
— Amanda K. Purdy, PhD, director of academic affairs

Partnership with University of Delaware
The University of Delaware has partnered with Fox Chase for the second year in a row to provide UD students with hands-on science and research experience. In line with the educational mission of the Center, the summer program paired Fox Chase research mentors with undergraduate students. The fellows – Deeanne Almeida, Elisabeth Habash, Yasmin Mann, and Carissa Walkosak – received training on how to analyze and present the results of their research and attended a series of talks about careers from guest speakers, including a genetic counselor and a surgeon. To help foster a sense of community, the four students lived together in a house near the Center. The program was supported by the university, Fox Chase, and Thomas Hofmann, a member of the Fox Chase Board of Directors and alumnus of UD.

Welcoming Paul M. Campbell
Award-winning pancreatic cancer researcher Paul M. Campbell, PhD, joined Fox Chase’s Cancer Biology Program in February. He has earned multiple clinical and translational grants and awards for his work on cancer signaling, progression, and metastasis. Previously he led a lab that studied tumorigenesis driven by the activation of the protooncogene K-Ras. At Fox Chase, Campbell has continued his research focus in these areas, with the overall objective of discovering and validating new targets for drug development and finding novel biomarkers for earlier detection and therapeutic monitoring.

Campbell is an assistant professor, and a member of The Marvin and Concetta Greenberg Pancreatic Cancer Institute at Fox Chase. He holds multiple patents related to cancer therapeutics.
PHILANTHROPY

- ALAN HABER - A SURPRISE GIFT
- IN VINO VITA
- THE LAUREL SOCIETY
- PILOT FUNDING
- NEW HEIGHTS FOR BOARD OF ASSOCIATES
- THE JOY OF GIVING BACK
Alan D. Haber, MD, FCCP, chief of pulmonary, sleep, and critical care medicine at Fox Chase, made the Special Pledge at this year’s In Vino Vita Benefit and Wine Auction especially memorable. Sharing lessons from his father and late mother—both of whom survived the Holocaust and later faced cancer—Haber made a $125,000 donation in their honor. Haber spoke about his parents’ lives, lessons, and the spirit of generosity they exemplified. When his father learned about the donation, he matched it, bringing the total gift to $250,000.

Their donation helped make Fox Chase one of the first in the country to offer Auris Health’s Monarch™ Platform, a robotic navigational bronchoscopy system that enables earlier diagnosis and treatment of lung cancer. •

The Fox Chase community is already looking forward to next year’s In Vino Vita, which is scheduled for April 6, 2019.

The Laurel Society
The Laurel Society, the premier donor society that honors Fox Chase’s most generous supporters, celebrated its 10th anniversary in 2018. Members of the society gathered in the fall at the Down Town Club in historic Old City Philadelphia for the annual Laurel Society recognition dinner. David Marshall received the Laurel Society Award for his service to Fox Chase, which includes 24 years on the Board of Directors. Fox Chase survivor Karen Cerrato shared her 20-plus year journey with head and neck cancer.
Pilot Funding

Pilot funding is essential for cancer researchers. It supports cutting-edge projects that offer the potential to extend science in new directions, and does so at a point where it may enable scientists to gather preliminary data needed to secure larger grants. In 2017 Fox Chase began a program to support early-stage researchers with pilot grants. The first five awards were announced in January 2018.

Donors who supported the special pledge at the 2017 In Vino Víta, the institution’s signature fundraising event, contributed funding to 10 projects over a two-year period.

The internal review committee evaluated 44 submissions. Effective pilot funding focuses on projects that are potentially paradigm-shifting; possess a high likelihood to lead to significant peer-reviewed funding; address the needs of the community Fox Chase serves; and/or translate laboratory findings into new clinical treatments.

The initial five grants provide funding of $75,000 per year.

Two awards were reserved for junior faculty. The following faculty members earned grants in the first round:

- Sergei Grivennikov, PhD, for his proposal, “Tumor adherent microbiota as a driver of tumor elicited inflammation in colorectal cancer”
- Neil Johnson, PhD, for his proposal, “Targeting the ubiquitin-regulated DNA damage response in BRCA1 mutant cancers”
- Richard Pomerantz, PhD, for his proposal, “Discovery of a Novel Reverse Transcriptase in Human Cells: Polymerase w”
- Vasily Studitsky, PhD, and Italo Tempera, PhD for their proposal, “Mechanisms of PARP1 action in transcription”
- Kuang Yi Wen, PhD, for her proposal, “To reduce cancer disparities: Mobile TXT to improve hormone therapy adherence in African American BCa survivors”

A second competition for five additional awards began in the fall of 2018.

“Funding for projects is highly competitive, and it can be difficult for junior faculty members to get their research off the ground. Private funding from generous donors can make all the difference in getting great ideas heard and helping junior faculty establish themselves.”
— Jonathan Chernoff, MD, PhD, senior vice president and chief scientific officer
She was treated for ovarian cancer in 2005, kidney cancer in 2010, and bladder cancer in 2015. Thankfully, each cancer was diagnosed at its earliest, most treatable stage, and she had a good outcome. Many of her doctors trained at Fox Chase Cancer Center, and although she was treated at other hospitals, she appreciates what Fox Chase has meant for her.

In 2015, Evie sold her share of the business to retire and spend time with her daughter, son-in-law, and granddaughter. She decided to support Fox Chase with a cash gift in 2018, and is looking forward to seeing the effect of her giving. She also revised her will to include Fox Chase and other institutions close to her heart, in order to leave a lasting impact. By including Fox Chase in her estate plan, Evie became a member of the Elizabeth Anderson Society – Fox Chase’s planned giving society. Gifts like Evie’s help sustain cancer science and medicine well into the future.

“It really takes a special person to work at Fox Chase. Everyone I met had a smile on their face and was incredibly positive. As a receptionist myself, I know it can be a struggle to stay positive all day long. It’s hard to make cancer a positive experience, but I never left feeling discouraged.”
— Tracy Gatto, breast cancer survivor and Paws for the Cause top fundraiser

“Philanthropy is very personal for me. Having lost family members and a close friend to melanoma, I had to get involved with the cause. I’m proud to support Fox Chase, whose care and commitment to patients is inspiring.”
— Neil F. Hall, melanoma survivor and donor

**The Joy of Giving Back**

In the 1960s, Evalind “Evie” Minor was a nurse, but her shifts were irregular. As a young mother facing a divorce, she needed a more consistent schedule to raise her daughter. She successfully transitioned to a corporate job, and in 1981 she founded EMSCO Scientific Enterprises, Inc. Evie is a three-time cancer survivor.

**PHILANTHROPY**
The Laurel Society

The Laurel Society is the signature donor society of Fox Chase Cancer Center, honoring the most generous supporters — individuals, corporations, foundations, community groups, and Fox Chase faculty and staff. Individuals demonstrate their commitment by providing annual support of $1,000 or more during Fox Chase’s fiscal year (July 1 through June 30). Corporations and community fundraisers become members at the $5,000+ level.

Founders’ Circle

$50,000+

Anonymous
Brenda & Edward Binion
Concetta Greenberg
Robert & Ernest Schaller Jr.
The Estate of Eugene Tol

Champions’ Circle

$10,000 - $24,999

Anonymous
Sheila & William J. Avery
The Estate of Alice C. Bassett
Lori A. Bienvenu
Carol A. & Michael D. Ellis
Theresa M. Carter
Reina S. & Michael A. Cohen
The Estate of Joan M. Davis
John A. & Divine A. Ellis
Mary & Joseph Fadoul
Amy E. & Leonard F. Feldman
Joseph A. Frick
Catherine R. Gatello
Doris & Arnold Glodbsen
Beverly T. & Stephen M. Godshall
Rachel E. & Eric M. Green

Guardians’ Circle

$5,000 - $9,999

Anonymous
Myra J. & J. Eliot Aplskind
Myra J. & John M. Ballinger Jr.
Judith K. & Arnold M. Bellows
Diane S. & Bernard L. Borghei
Robert J. & Brenda Brennan
The Estate of Edith Brehm
Delbert E. Browning Jr.
Lizbeth E. & Brunswick Millar
Pamela & Robert L. Byers

DOROTORS

Dorothy S. Dryburgh
Margaret & Anthony J. Diasio
Frank J. Crowley
Diane & Warren Chaiken
Paula & Bob Cardea
Elinor & James M. Buck III
George M. Beschen
Mildred J. & John R. Barr
Barry Taitelman
Peggy & Brian Strecker
Elaine & Mark L. Sobczak
Amanda T. & Filippo T. Troia
Brando N. & Rich
Ny-Yong

Partners’ Circle

$1,000 - $2,499

Allison Agen & Eric Brench
Lorelie R. & Benjamin J. Essel
D. Furl & Sue Berman
Anonymous
Eleni G. & Michael Ar analysts
Sandy Adams-Arends
Susan A. Bykes
Suzanne Balbirer
Lisa Broida Bailey
Sandy Askey-Adams
Ellen G. & Michael E. Araten
Frank C. Wilhelm
Margaret von Mehren
Lynn Tucker
Margaret von Mehren

Patrons’ Circle

$500 - $1,000

Judy & Al Kiefer
Judith J. & Robert J. Bennett
Lizanne & Timothy J. Bernhold
Virginia V. & Leon L. Boyer
Kathleen & Anthony Baccella
Scott Boivert
Ariane L. & Michael E. Araten
Joyce & Michael A. Aratan
Elizabeth & Hugh Bowerman
Wendy J. & Edward T. Bridget
Jeannete Brockman
Thomas F. Bridgess
Albert Brookes
Jen & John B. Berliner
Brenda N. & Rich

Advocates’ Circle

$25 - $299

Anonymous
The Estate of William Barber
Magpie & Bob Beck
Bobby Ann & R. Reginald Bishop
Don & D. Jeffrey D. Byers
David Campbell
Janet F. & Paul E. Engstrom
Susan O. & Richard J. Fisher
Josch Frank
Donna & Stephen M. Fuga
Mary Jo & Brian F. Granet
Kay & Thomas W. Hofmann
Charlene T. & Karl G. Halbreich
Brenda N. & William J. Avery
Marianne & Dominic A. Cipollina
Margie L. & Dapper
Donald J. & Emily L. Carney
Sharon & Kevin Coghlan
Arthur Cohen
Elizabeth R. & Richard Cohen
Jane & Robert Cohn
Jean I. & Frederick M. Cohen
Richard D. Catolico
Audrey & Donald C. Carry
S. Doris & Neil B. Cashore
Debra & Richard Cooper
Pamela & Fred S. Cooper
Megan & Jonathan Craig
Margaret & Jay C. Cray
Mary A. & Craig
Elsie & Marco Caramanica
Catherine Cus Robert Czyzewicz
When & Daniel J. De Nola
Antoinette & William DaCarlo
Elena Demdova
Crystal S. Deninger
Maria Delfaut & All R. Offerman
Diane M. & Kenneth J. Perich
Patricia & Ward & Diseasa
Martin J. Decker
Airin & B. Dalich
Michael D. & Michael D. Dubrow
Roland L. Derbruck
Rita E. & Charles D. Denley
Donald E. F. De-cross
Keith M. Ferko
Kathleen E. Fries
Laura E. & Patrick J. Fries
Elizabeth & Hugh Bowerman
Wendy J. & Edward T. Bridget
Jeannete Brockman
Thomas F. Bridgess
Albert Brookes
Jen & John B. Berliner
Brenda N. & Rich

ANNUAL REPORT 2018 | PREVAIL | FOX CHASE CANCER CENTER

372

39 FOX CHASE CANCER CENTER | PREVIAL | ANNUAL REPORT 2018
DONORS

Melanie J. Norris
John G. Nalesnik
Lainie Martin
Jeffrey Markowitz
Nicholas Panos
Heidi & Scot D. Pannepacker
Ephe A. Olliver
Claire & Thomas J. Mulvaney
Sujana Movva
Kashmira & Ashok Modi
Pam & David Miller
David R. McShane
Christopher W. McNichol
Angeline & Gerald J. Manna
Kristen J. & Christopher J. Manley
Felix Mandato
Chin Tsai Lu
Jerome Lomurno
Linda R. & Theodore Liebman
Sameer A. John J. Portnoy
Gricoski lo-Gricoski & Zelda R. Stern
Lindy Snider & Larry R. Kaiser
Keiko & John R. Simon
Thomas Seaman
Cecile H. Sculthorpe
Michelle & Stephen A. Scialdone
Marilyn & Alan C. Schwedel
Jessie Schol & Sarah Schol
Angela M. Lynch
Susan B. Denzin
Nancy Markowich
Angela M. Lynch
Nancy Markowich
Richard G. Blumberg
Karen Ferraro
Michael King
Catherine A. & Robert N. Smith
Michael A. & Jeanne L. Spratt
Richard R. & Donna S. Swift
Kathleen Carney
Geraldine M. Kozempel
Marina Ross
Kathleen Carney
Geraldine M. Kozempel
Marina Ross
Kathleen Carney
Geraldine M. Kozempel
Marina Ross
Kathleen Carney
Geraldine M. Kozempel
Marina Ross
Kathleen Carney
Geraldine M. Kozempel
Marina Ross
Kathleen Carney
Geraldine M. Kozempel
Marina Ross
Kathleen Carney
Geraldine M. Kozempel
Marina Ross
Kathleen Carney
Geraldine M. Kozempel
Marina Ross
Kathleen Carney
Geraldine M. Kozempel
Marina Ross
Kathleen Carney
Geraldine M. Kozempel
Marina Ross
Kathleen Carney
Geraldine M. Kozempel
Marina Ross
Kathleen Carney
Geraldine M. Kozempel
Marina Ross
Kathleen Carney
Geraldine M. Kozempel
Marina Ross
Kathleen Carney
Geraldine M. Kozempel
Marina Ross
Kathleen Carney
Geraldine M. Kozempel
Marina Ross
Kathleen Carney
Geraldine M. Kozempel
Marina Ross
Kathleen Carney
Geraldine M. Kozempel
Marina Ross
Kathleen Carney
Geraldine M. Kozempel
Marina Ross
Kathleen Carney
Geraldine M. Kozempel
Marina Ross
Kathleen Carney
Geraldine M. Kozempel
Marina Ross
Kathleen Carney
Geraldine M. Kozempel
Marina Ross
Kathleen Carney
Geraldine M. Kozempel
Marina Ross
Kathleen Carney
Geraldine M. Kozempel
Marina Ross
Kathleen Carney
Geraldine M. Kozempel
Marina Ross
Kathleen Carney
Geraldine M. Kozempel
Marina Ross
Kathleen Carney
Geraldine M. Kozempel
Marina Ross
Kathleen Carney
Geraldine M. Kozempel
Marina Ross
Kathleen Carney
Geraldine M. Kozempel
Marina Ross
Kathleen Carney
Geraldine M. Kozempel
Marina Ross
Kathleen Carney
Geraldine M. Kozempel
Marina Ross
Kathleen Carney
Geraldine M. Kozempel
Marina Ross
Kathleen Carney
Geraldine M. Kozempel
Marina Ross
Kathleen Carney
Geraldine M. Kozempel
Marina Ross
Kathleen Carney
Geraldine M. Kozempel
Marina Ross
Kathleen Carney
Geraldine M. Kozempel
Marina Ross
Kathleen Carney
Geraldine M. Kozempel
Marina Ross
Kathleen Carney
Geraldine M. Kozempel
Marina Ross
Kathleen Carney
Geraldine M. Kozempel
Marina Ross
Kathleen Carney
Geraldine M. Kozempel
Marina Ross
Kathleen Carney
Geraldine M. Kozempel
Marina Ross
Kathleen Carney
Geraldine M. Kozempel
Marina Ross
Kathleen Carney
Geraldine M. Kozempel
Marina Ross
Kathleen Carney
Geraldine M. Kozempel
Marina Ross
Kathleen Carney
Geraldine M. Kozempel
Marina Ross
Kathleen Carney
Geraldine M. Kozempel
Marina Ross
Kathleen Carney
Geraldine M. Kozempel
Marina Ross
Kathleen Carney
Geraldine M. Kozempel
Marina Ross
Kathleen Carney
Geraldine M. Kozempel
Marina Ross
Kathleen Carney
Geraldine M. Kozempel
Marina Ross
Kathleen Carney
Geraldine M. Kozempel
Marina Ross
Kathleen Carney
Geraldine M. Kozempel
Marina Ross
Kathleen Carney
Geraldine M. Kozempel
Marina Ross
Kathleen Carney
Geraldine M. Kozempel
Marina Ross
Kathleen Carney
Geraldine M. Kozempel
Marina Ross
Kathleen Carney
Geraldine M. Kozempel
Marina Ross
Kathleen Carney
Geraldine M. Kozempel
Marina Ross
Kathleen Carney
Geraldine M. Kozempel
Marina Ross
Kathleen Carney
Geraldine M. Kozempel
Marina Ross
Kathleen Carney
Geraldine M. Kozempel
Marina Ross
Kathleen Carney
Geraldine M. Kozempel
Marina Ross
Kathleen Carney
Geraldine M. Kozempel
Marina Ross
Kathleen Carney
Geraldine M. Kozempel
Marina Ross
Kathleen Carney
Geraldine M. Kozempel
Marina Ross
Kathleen Carney
Geraldine M. Kozempel
Marina Ross
Kathleen Carney
Geraldine M. Kozempel
Marina Ross
Kathleen Carney
Geraldine M. Kozempel
Marina Ross
Kathleen Carney
Geraldine M. Kozempel
Marina Ross
Kathleen Carney
Geraldine M. Kozempel
Marina Ross
Kathleen Carney
Geraldine M. Kozempel
Marina Ross
Kathleen Carney
Geraldine M. Kozempel
Marina Ross
Kathleen Carney
Geraldine M. Kozempel
Marina Ross
Kathleen Carney
Geraldine M. Kozempel
Marina Ross
Kathleen Carney
Geraldine M. Kozempel
Marina Ross
Kathleen Carney
Geraldine M. Kozempel
Marina Ross
Kathleen Carney
Geraldine M. Kozempel
Marina Ross
Kathleen Carney
Geraldine M. Kozempel
Marina Ross
Kathleen Carney
Geraldine M. Kozempel
Marina Ross
Kathleen Carney
Geraldine M. Kozempel
Marina Ross
Kathleen Carney
Geraldine M. Kozempel
Marina Ross
Kathleen Carney
Geraldine M. Kozempel
Marina Ross
Kathleen Carney
Geralda C. J. R. Nobile
Barbara J. Goeman
Nancy L. Alpers
Diana M. & Donald R. Klimstra
Diana M. & Donald R. Klimstra
Diana M. & Donald R. Klimstra
Diana M. & Donald R. Klimstra
Cynthia Ferraro
Wendy B. Fox & Remy L. Fox
A. Anne Grace
Anna Venero
Norman F. Wats
Sukhmati & Timothy, Weckesser
Nam/Weiss
Joyza C. Zimmerman
Talkwest
## FINANCIALS

### 2018 BY THE NUMBERS
- **Scientific Publications**: 707
- **Outpatient Visits**: 113,546
- **New Patients**: 8,652
- **New Faculty Members**: 23

### PHILANTHROPY SNAPSHOT
- **Total Philanthropic Support**: $14,400,000
- **Raised at IN VINO VITA**: $1,700,000
- **Total Donors**: 10,201
- **Current Donors Who Have Given 30+ Years**: 612
- **Board of Associates Total Gifts**: $711,217

### VOLUNTEER SNAPSHOT
- **Volunteers**: 524
- **Total Volunteer Hours**: 84,741
- **Volunteer Department Budget**: $269,413
- **Value of Hours**: $2,092,255
- **Net Value Added to Fox Chase**: $1,822,842

### RESEARCH SNAPSHOT
- **Active Funded Projects**
  - **Funding Source**
  - **Number of Projects**: 186
  - **Direct Costs**: $26,285,063
  - **Total Costs**: $41,012,546

### CLINICAL SNAPSHOT (In Thousands)
- **Patient Care Revenue**
  - **Hospital**: $365,219
  - **Physicians**: $35,326
  - **Philanthropy, Outreach & Other**: $11,574
  - **Total**: $412,119

### OPERATING EXPENSES (In Thousands)
- **Direct Patient Care**: $292,399
- **Support Services**: $17,929
- **Administrative & General**: $40,707
- **Capital Related Costs**: $9,106
- **Maintenance & Plant Operations**: $11,469
- **Total**: $371,610

### KEY PATIENT CARE STATISTICS
- **New Patients**: 8,652
- **Hospital Admissions**: 4,304
- **Chemotherapy Infusions & Related Procedures**: 63,089
- **Radiation Therapy Treatments**: 26,616
- **Surgical Procedures**: 4,980

### RESEARCH SNAPSHOT
- **Active Funded Projects**
  - **Funding Source**
  - **Number of Projects**: 186
  - **Direct Costs**: $26,285,063
  - **Total Costs**: $41,012,546

### ACTIVELY ENROLLING CLINICAL RESEARCH STUDIES
- **302**

### INVESTIGATOR INITIATED CLINICAL RESEARCH STUDIES
- **91**

### ANNUAL REPORT 2018 | PREVAIL | FOX CHASE CANCER CENTER
FINANCIALS

TYPES OF CANCERS TREATED

- Pancreas: 3%
- Head & Neck: 3%
- Lymphoma: 3%
- Bladder: 5%
- Kidney: 5%
- Skin: 5%
- Colorectal: 6%
- Gynecological: 8%
- Lung: 12%
- Prostate: 15%
- Breast: 19%
- Other: 16%

FY18 PAYER MIX

- Commercial: 42%
- Medicare: 36%
- Medicare Managed Care: 13%
- Medicaid: 8%
- Self-Pay/Other: 1%

Numbers represent Fiscal Year 2018
1904
A group of physicians and businessmen signed the charter to establish the American Oncologic Hospital. The hospital opened on January 4, 1905, becoming one of the first hospitals in the country devoted exclusively to treating cancer.

1925
Stanley P. Reitman, MD, chief pathologist at Lankenau Hospital, founded the Lankenau Hospital Research Institute. In 1945 it would evolve into the Institute for Cancer Research.

1959
David A. Hungerford, a doctoral student at the Institute for Cancer Research, and Peter C. Nowell, MD, from the University of Pennsylvania, discovered what would become known as the Philadelphia Chromosome. It was the first conclusive evidence that cancer is a genetic disorder of somatic cells.

1967
Baruch S. Blumberg, MD, PhD, made the world-changing discovery of the hepatitis B virus, a major cause of primary liver cancer, the fifth most common cancer worldwide. With his two years Blumberg and Irving Millman, PhD, developed a vaccine to prevent the virus. It was the first vaccine that prevents a form of cancer in humans. Blumberg is credited with preventing millions of cases of liver cancer over the ensuing decades. He received the Nobel Prize in Medicine in 1976, and he and Millman were elected to the National Inventors Hall of Fame in 1993.

1974
The American Oncologic Hospital and the Institute for Cancer Research united to form Fox Chase Cancer Center. That same year, Fox Chase became one of the first institutions to earn the National Cancer Institute’s site designation as a Comprehensive Cancer Center.

2004
Fox Chase’s Irwin A. Rose, PhD, and collaborators Aoram Harshil, MD, PhD, and Aaron Clechanover, MD, PhD, received the Nobel Prize in Chemistry in recognition of their work together at Fox Chase from the 1970s through the early 1980s. The group discovered one of the cell’s most important cyclical processes: how proteins are broken down and recycled.